Skylar Jeremias

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and real-world data, with findings reinforced by new results presented at Digestive Disease Week 2025.

As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.

The American Society for Gastrointestinal Endoscopy has issued new guidelines for diagnosing and managing gastroesophageal reflux disease (GERD), with updated recommendations on endoscopy use, lifestyle changes, and endoscopic treatments like transoral incisionless fundoplication.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.

Long-term exposure to multiple air pollutants may silently wreak havoc on your gut, significantly increasing the risk of gastrointestinal diseases and underscoring the urgent need for public health policies that clean the air we breathe and protect our digestive health.

Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.

Healthy dietary patterns, rich in fruits, vegetables, whole grains, and legumes, may significantly reduce the risk and mortality of gastrointestinal cancers, while diets high in red and processed meats, alcohol, and sugary beverages can increase these risks.

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients aged 2 and older without early treatment.

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential for enhancing targeted treatment and sustained release of medications in the gastrointestinal (GI) tract, particularly for managing inflammatory bowel disease (IBD).

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual meeting.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration challenges, with key selection factors like patient age and gene copy number, according to Julie Parsons, MD, a professor and neurologist from the University of Colorado School of Medicine.

Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.

As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.

Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.

The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis (AD), offering viable alternatives to systemic therapies.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, highlights upcoming discussions on patient engagement, formulary management, and policy changes, including the Inflation Reduction Act.

As managed care pharmacy navigates rapid transformations in policies, high-cost drug strategies, and innovative therapies, the upcoming AMCP annual meeting will provide critical insights into legislative impacts, drug affordability, formulary design, and emerging treatment trends.

Access to timely treatment for spinal muscular atrophy (SMA) remains a challenge, with barriers including delays in diagnosis, frequent treatment needs, and insurance coverage gaps, which impact patient care and quality of life.

Celiac disease can lead to both disease-related and diet-induced vitamin deficiencies, making it crucial for patients to receive tailored nutritional management to ensure adequate nutritional intake.

Adults with irritable bowel syndrome (IBS) who smoke may face heightened challenges in quitting due to severe IBS symptoms and anxiety sensitivity, which increase perceived barriers and reinforce the belief that smoking helps relieve negative emotions.

A multidisciplinary approach, early diagnosis, and comprehensive caregiver education are crucial in effectively managing spinal muscular atrophy (SMA).

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to a systematic review.

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments, increasing biosimilar adoption, and implementing policies that reduce financial disparities and improve long-term patient outcomes.

Advancements in ocular technology, teleretinal imaging, and low-vision aids, including artificial intelligence-powered smart glasses, were highlighted in research posters at the Southeastern Congress of Optometry 2025.

Health care providers must recognize and address the high prevalence of anxiety in gastroenterology (GI) and hepatology outpatients, as its bidirectional relationship with chronic conditions can significantly impact both physical and emotional wellbeing, according to a global review.

Effective communication, cultural competence, and patient advocacy are keys to overcoming language barriers in eye care, as highlighted in a presentation at the Southeastern Congress of Optometry 2025.